INmune Bio Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Net Loss: Approximately $1.3 million for Q2 2026, a significant decrease from $24.5 million in Q2 2025, which included a $16.5 million impairment charge.

R&D Expenses: Reported as a benefit of approximately $800,000 for Q2 2026, compared to $5.8 million in Q2 2025, attributed to an Australian R&D tax rebate.

General and Administrative Expenses: Stable at approximately $2.3 million for both Q2 2026 and Q2 2025.

Cash Position: As of June 30, 2026, cash and cash equivalents were approximately $18.4 million. An additional $4.2 million in tax rebates was received post-quarter, extending cash runway into Q2 2027.

2Strategic Updates and Business Highlights

Ebstracel Progress: Received formal alignment from the MHRA and approval for a pediatric investigation plan. A marketing authorization application (MAA) is expected to be submitted by Q3 or early Q4 2026, seeking conditional approval for RDEB.

Manufacturing Milestones: Successfully processed the first commercial-ready umbilical cord and established a scalable supply chain through partnerships, enhancing operational readiness for regulatory submissions.

XPro Developments: Achieved FDA Fast Track designation for early Alzheimer's disease, with promising Phase 2 trial results showing statistically significant treatment effects on MRI biomarkers.

3Forward Guidance and Outlook

Upcoming Milestones:

Submission of the UK MAA for Ebstracel by the end of Q3 or early Q4 2026.

Plans to submit to the EMA in early 2027 and a BLA to the FDA in Q1 2027.

Continued advancement of XPro's registrational strategy, with potential partnerships under evaluation.

Market Potential: The company anticipates a patient population of approximately 800 in the UK for RDEB, with pricing expected between $400,000 to $500,000 per year per child.

4Bad News, Challenges, or Points of Concern

Market Valuation: Concerns were raised by investors regarding the current share price, which some believe does not reflect the company's potential value based on recent developments.

Burn Rate: The company projects a monthly burn rate of $1 million to $1.5 million, which may increase as R&D rebates are not expected to continue at the same level.

Regulatory Risks: While the company has made significant progress, the success of upcoming regulatory submissions remains uncertain and could impact future operations and funding needs.

5Notable Q&A Insights

Trial Clarifications: Management clarified that the open-label Phase 3 trial for Ebstracel will serve both safety and confirmation purposes, with an expected enrollment of 40-45 patients.

Regulatory Hurdles: Management expressed confidence in meeting regulatory expectations, particularly concerning the primary endpoints of pain and itch relief for RDEB patients.

Investor Sentiment: Management acknowledged the undervaluation of the company and emphasized a disciplined approach to capital management, focusing on judicious spending and resource allocation as they move towards product approval. Overall, INmune Bio is positioned for significant regulatory milestones with its Ebstracel and XPro programs, while maintaining a cautious approach to financial management amidst ongoing market and operational challenges.